C-reactive protein and cardiovascular diseases: a synthesis of studies based on different designs.
作者信息
Liu Chunyu, Li Chihua
机构信息
Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Xueyuan Road, Haidian District, Beijing 100191, China.
Survey Research Center, Institute for Social Research, University of Michigan, 426 Thompson St, Ann Arbor, MI 48104, USA.
出版信息
Eur J Prev Cardiol. 2023 Oct 26;30(15):1593-1596. doi: 10.1093/eurjpc/zwad116.
Abstract
摘要
相似文献
1
C-reactive protein and cardiovascular diseases: a synthesis of studies based on different designs.C反应蛋白与心血管疾病：基于不同设计的研究综述
Eur J Prev Cardiol. 2023 Oct 26;30(15):1593-1596. doi: 10.1093/eurjpc/zwad116.
2
C-reactive protein, subclinical atherosclerosis, and risk of cardiovascular events.C反应蛋白、亚临床动脉粥样硬化与心血管事件风险
Arterioscler Thromb Vasc Biol. 2002 Oct 1;22(10):1512-3. doi: 10.1161/01.atv.0000038145.59548.85.
3
Is it important to measure or reduce C-reactive protein in people at risk of cardiovascular disease?测量或降低心血管疾病风险人群的C反应蛋白是否重要？
Eur Heart J. 2012 Sep;33(18):2258-64. doi: 10.1093/eurheartj/ehs168. Epub 2012 Jul 5.
4
Commentary on ICEBERG.关于“冰山”的评论。
J Clin Hypertens (Greenwich). 2007 Jul;9(7):557. doi: 10.1111/j.1524-6175.2007.07327.x.
5
Does C-reactive protein represent an oxidative stress marker in cardiovascular disease?C反应蛋白是否代表心血管疾病中的氧化应激标志物？
Int J Clin Pract. 2003 Apr;57(3):252.
6
C-reactive protein: eighty years from discovery to emergence as a major risk marker for cardiovascular disease.C反应蛋白：从发现到成为心血管疾病主要风险标志物的八十年历程
Clin Chem. 2009 Feb;55(2):209-15. doi: 10.1373/clinchem.2008.119214. Epub 2008 Dec 18.
7
Metabolic biomarkers for predicting cardiovascular disease.用于预测心血管疾病的代谢生物标志物。
Vasc Health Risk Manag. 2013;9:37-45. doi: 10.2147/VHRM.S30378. Epub 2013 Jan 29.
8
Is pentraxin 3 a cardiovascular marker in patients with chronic Chagas disease?在慢性恰加斯病患者中，五聚素3是一种心血管标志物吗？
Int J Cardiol. 2015;190:233-5. doi: 10.1016/j.ijcard.2015.04.106. Epub 2015 Apr 16.
9
Hold, raise, or fold: C-reactive protein, hormone therapy, and cardiovascular risk.坚持、采用还是放弃：C反应蛋白、激素疗法与心血管风险。
Menopause. 2011 Jan;18(1):8-10. doi: 10.1097/gme.0b013e3181ff3e96.
10
C-reactive protein for the prediction of cardiovascular risk: ready for prime-time?C反应蛋白用于预测心血管风险：准备好进入黄金时段了吗？
CMAJ. 2004 May 11;170(10):1563-5. doi: 10.1503/cmaj.1031968.
引用本文的文献
1
The Effects of Colchicine on Lipoprotein(a) and Oxidized Phospholipid Associated Cardiovascular Disease Risk.秋水仙碱对脂蛋白（a）及氧化磷脂相关心血管疾病风险的影响。
Eur J Prev Cardiol. 2024 Oct 30. doi: 10.1093/eurjpc/zwae355.
2
Serum high sensitive C-reactive protein level and its correlation with lipid profile among dyspeptic patients with or without infection in East Gojjam zone, Ethiopia.埃塞俄比亚东戈贾姆地区消化不良患者（无论有无感染）的血清高敏C反应蛋白水平及其与血脂谱的相关性
Front Cardiovasc Med. 2024 Sep 26;11:1470993. doi: 10.3389/fcvm.2024.1470993. eCollection 2024.
3
Interleukin-6 positively correlates with cardiovascular disease predictor algorithms and biomarker in rheumatoid arthritis patients.白细胞介素-6 与类风湿关节炎患者心血管疾病预测算法和生物标志物呈正相关。
J Cell Mol Med. 2024 Aug;28(16):e70028. doi: 10.1111/jcmm.70028.
4
Frailty and Cardiovascular Health.虚弱与心血管健康。
J Am Heart Assoc. 2024 Aug 6;13(15):e031736. doi: 10.1161/JAHA.123.031736. Epub 2024 Jul 26.
5
Life's Essential 8 is inversely associated with high-sensitivity C-reactive protein.“生命要素 8”与高敏 C 反应蛋白呈负相关。
Sci Rep. 2024 Jul 1;14(1):15024. doi: 10.1038/s41598-024-65977-3.
6
Sex-specific relationships of inflammatory biomarkers with blood pressure in older adults.炎症生物标志物与老年人血压的性别特异性关系。
Geroscience. 2024 Oct;46(5):4603-4614. doi: 10.1007/s11357-024-01170-8. Epub 2024 May 8.
7
C-Reactive Protein and Long-Term Prognosis in Adult Patients with Congenital Heart Disease.C反应蛋白与成人先天性心脏病患者的长期预后
J Clin Med. 2024 Apr 11;13(8):2199. doi: 10.3390/jcm13082199.
8
Peripheral immune function and Alzheimer's disease: a living systematic review and critical appraisal.外周免疫功能与阿尔茨海默病：一项实时系统评价和批判性评估。
Mol Psychiatry. 2024 Jun;29(6):1895-1905. doi: 10.1038/s41380-023-02355-x. Epub 2023 Dec 15.
9
Innate and Adaptive Immunity-Related Markers as Predictors of the Short-Term Progression of Subclinical Atherosclerosis in Middle-Aged Patients.先天和适应性免疫相关标志物作为预测中年患者亚临床动脉粥样硬化短期进展的指标。
Int J Mol Sci. 2023 Jul 30;24(15):12205. doi: 10.3390/ijms241512205.
本文引用的文献
1
Mendelian randomization analysis of 37 clinical factors and coronary artery disease in East Asian and European populations.孟德尔随机化分析东亚和欧洲人群 37 种临床因素与冠心病的关系。
Genome Med. 2022 Jun 14;14(1):63. doi: 10.1186/s13073-022-01067-1.
2
Modifiable lifestyle risk factors and C-reactive protein in patients with coronary artery disease: Implications for an anti-inflammatory treatment target population.可改变的生活方式风险因素与冠心病患者的 C-反应蛋白：抗炎治疗目标人群的意义。
Eur J Prev Cardiol. 2021 Apr 10;28(2):152–158. doi: 10.1177/2047487319885458. Epub 2019 Nov 10.
3
Effects of individual and integrated cumulative burden of blood pressure, glucose, low-density lipoprotein cholesterol, and C-reactive protein on cardiovascular risk.个体及综合累积血压、血糖、低密度脂蛋白胆固醇和 C 反应蛋白负担对心血管风险的影响。
Eur J Prev Cardiol. 2022 Feb 19;29(1):127-135. doi: 10.1093/eurjpc/zwaa052.
4
Use of directed acyclic graphs (DAGs) to identify confounders in applied health research: review and recommendations.应用健康研究中使用有向无环图（DAG）识别混杂因素：综述与建议。
Int J Epidemiol. 2021 May 17;50(2):620-632. doi: 10.1093/ije/dyaa213.
5
Global assessment of C-reactive protein and health-related outcomes: an umbrella review of evidence from observational studies and Mendelian randomization studies.C 反应蛋白与健康结局的全球评估：来自观察性研究和孟德尔随机化研究的证据的伞状综述。
Eur J Epidemiol. 2021 Jan;36(1):11-36. doi: 10.1007/s10654-020-00681-w. Epub 2020 Sep 25.
6
C-reactive protein and cardiovascular disease: From animal studies to the clinic (Review).C反应蛋白与心血管疾病：从动物研究到临床（综述）
Exp Ther Med. 2020 Aug;20(2):1211-1219. doi: 10.3892/etm.2020.8840. Epub 2020 Jun 4.
7
Plasma Biomarkers to Predict Cardiovascular Outcome in Patients With Peripheral Artery Disease: A Systematic Review and Meta-Analysis.外周动脉疾病患者心血管结局预测的血浆生物标志物：系统评价和荟萃分析。
Arterioscler Thromb Vasc Biol. 2020 Sep;40(9):2018-2032. doi: 10.1161/ATVBAHA.120.314774. Epub 2020 Jul 9.
8
Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction.心梗后小剂量秋水仙碱的疗效和安全性。
N Engl J Med. 2019 Dec 26;381(26):2497-2505. doi: 10.1056/NEJMoa1912388. Epub 2019 Nov 16.
9
Low-Dose Methotrexate for the Prevention of Atherosclerotic Events.低剂量甲氨蝶呤预防动脉粥样硬化事件。
N Engl J Med. 2019 Feb 21;380(8):752-762. doi: 10.1056/NEJMoa1809798. Epub 2018 Nov 10.
10
Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty.炎老化：与衰老、心血管疾病和虚弱有关的慢性炎症。
Nat Rev Cardiol. 2018 Sep;15(9):505-522. doi: 10.1038/s41569-018-0064-2.
Zotero 插件